Poltreg S.A.
PTG.WA
Get informed when a big investor buys or sells
+ FollowMarket Cap$115.37M
Close$
Share Statistics
| Market cap | $115.37 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.58 |
| Beta | 0.83 |
| Outstanding Shares | 5,699,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.88 |
|---|---|
| PEG | 11.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Poltreg S.A.
34 employees
CEO: Piotr Trzonkowsk Poltreg S.A. is a biotechnology enterprise based in Gdansk, Poland, specializing in the creation of therapeutic solutions for autoimmune conditions. The company's research and development efforts are centered on harnessing T-regulatory c...